Cardio-oncology Related to Heart Failure

Heart Failure Clinics
13, 297-309
DOI: 10.1016/j.hfc.2016.12.002

Citation Report

#	Article	IF	Citations
1	Left Ventricular Dysfunction in CancerÂTreatment. JACC: Heart Failure, 2018, 6, 87-95.	4.1	37
2	Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Molecular and Cellular Toxicology, 2018, 14, 247-254.	1.7	11
3	Light control of RTK activity: from technology development to translational research. Chemical Science, 2020, 11, 10019-10034.	7.4	7
4	The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications. Frontiers in Pharmacology, 2021, 12, 701390.	3.5	19
5	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213
6	Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. Methodist DeBakey Cardiovascular Journal, 2021, 15, 250.	1.0	7
7	Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity. Biomedicines, 2022, 10, 520.	3.2	14
9	Exploring Key Genes and Pathways of Cardiac Hypertrophy Based on Bioinformatics. Disease Markers, 2022, 2022, 1-8.	1.3	3
10	Cardio-oncology: Implications for Clinical Practice for Women. Current Cardiology Reports, 2022, 24, 1685-1698.	2.9	1
11	EGFR inhibition leads to enhanced desmosome assembly and cardiomyocyte cohesion via ROCK activation. JCI Insight, 2023, 8, .	5.0	4
12	Effect of variable left ventricular ejection fraction assessed by equilibrium radionuclide angiocardiography using different software packages on the diagnosis of cardiotoxicity in patients with cancer. Journal of Nuclear Cardiology, 2024, 31, 101782.	2.1	0
13	Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study. Therapeutic Advances in Medical Oncology, 2024, 16, .	3.2	0